Insulin in Treatment of Diabetes Mellitus With Pregnancy
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The prevalence of diabetes melilites is rapidly increasing over years and consequently during
pregnancy. In 2017, there were 21.3 million pregnant women who experienced hyperglycemia, of
which 86.4% of them were diagnosed with gestational diabetes melilites.
Pregnancy in women with diabetes is associated with an intensification in adverse maternal,
fetal and perinatal outcomes including spontaneous abortions, congenital malformations,
preterm labor, and macrosomia. Several studies have confirmed that poor glycemic control in
women with either gestational, type 1 or type 2 diabetes during pregnancy is associated with
poor pregnancy outcomes. In the same line, proper glycemic control before, early, and through
all pregnancy markedly improves both maternal and fetal outcomes.
Insulin therapy is the standard treatment of diabetes melilites with the pregnancy if dietary
control and exercise fail. However, insulin therapy has its difficulties like approaches to
mimicking postprandial insulin release, providing adequate background insulin, balancing
insulin dosage, food, activity, hypoglycemic episodes, overall glycemia. This is always a
struggle for doctors and patients and much affecting their lifestyle